NASDAQ: TSBXTurnstone Biologics Corp Stock
$0.33+0.00 (+0%)
Updated Apr 21, 2025
TSBX Price
$0.33
Fair Value Price
N/A
Market Cap
$7.64M
52 Week Low
$0.32
52 Week High
$3.39
P/E
-0.11x
P/B
0.24x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$70.84M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.28
Operating Cash Flow
-$67M
Beta
1.23
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TSBX Overview
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TSBX's potential to beat the market
- TSBX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TSBX
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important TSBX news, forecast changes, insider trades & much more!
TSBX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TSBX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TSBX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TSBX is good value based on its book value relative to its share price (0.24x), compared to the US Biotechnology industry average (4.04x)
P/B vs Industry Valuation
TSBX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TSBX due diligence checks available for Premium users.
Valuation
TSBX fair value
Fair Value of TSBX stock based on Discounted Cash Flow (DCF)
Price
$0.33
Fair Value
-$0.24
Undervalued by
239.20%
TSBX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TSBX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.11x
Industry
-184.27x
Market
27.14x
TSBX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.24x
Industry
4.04x
TSBX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TSBX's financial health
Profit margin
Revenue
$0.0
Net Income
-$12.9M
Profit Margin
0%
TSBX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$40.1M
Liabilities
$8.7M
Debt to equity
0.28
TSBX's short-term assets ($34.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TSBX's short-term assets ($34.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TSBX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.5M
Investing
$21.3M
Financing
$0.0
TSBX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TSBX vs Biotech Stocks
Turnstone Biologics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.